{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:14:24Z","timestamp":1792012464107,"version":"4.4.0"},"reference-count":33,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100024580","name":"Orion Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024580","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Vet Pharm &amp; Therapeutics"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    This exploratory randomized crossover study investigated pharmacokinetic interactions, functional alertness, and cardiovascular safety of tasipimidine oral solution administered alone and in combination with fluoxetine in healthy Beagle dogs (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20098; 4 dogs per dose level), with a 7\u2010day washout between phases. Dogs received single oral doses of tasipimidine (20 or 30\u2009\u03bcg\/kg) alone and following single or repeated fluoxetine administration (~1\u2009mg\/kg\/day for 12\u2009days). Functional alertness was assessed using a semi\u2010quantitative, observer\u2010based scale evaluating responsiveness and ability to walk. Cardiovascular effects were monitored by telemetry, including heart rate, blood pressure, and ECG. Co\u2010administration with fluoxetine increased tasipimidine exposure, with Cmax and AUC\n                    <jats:sub>0\u201024h<\/jats:sub>\n                    rising approximately 1.3\u20131.4\u2010fold after single fluoxetine dosing and up to 1.4\u2010fold at the 30\u2009\u03bcg\/kg tasipimidine dose after repeated fluoxetine administration; these changes were variable and not consistently statistically significant. Reduced alertness and transient mild ataxia were more frequent at 30\u2009\u03bcg\/kg, whereas the 20\u2009\u03bcg\/kg dose showed minimal sedative effects. Tasipimidine reduced heart rate by 30\u201352\u2009bpm and mean arterial pressure by 13\u201321\u2009mmHg. No clinically relevant ECG abnormalities were detected. The increased tasipimidine exposure is likely related to metabolic inhibition by fluoxetine. Overall, concurrent use was well tolerated, supporting a reduced tasipimidine dose (20\u2009\u03bcg\/kg) when combined with fluoxetine.\n                  <\/jats:p>","DOI":"10.1111\/jvp.70098","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:06:52Z","timestamp":1784117212000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Concurrent Use of Tasipimidine Oral Solution and Fluoxetine in Dogs"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2599-6615","authenticated-orcid":false,"given":"Jenni","family":"Lindstedt","sequence":"first","affiliation":[{"name":"Animal Health Research and Development Orion Pharma  Espoo Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3504-122X","authenticated-orcid":false,"given":"Jouko M.","family":"Levijoki","sequence":"additional","affiliation":[{"name":"Animal Health Research and Development Orion Pharma  Espoo Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2556-510X","authenticated-orcid":false,"given":"Johanna","family":"Tuunainen","sequence":"additional","affiliation":[{"name":"Animal Health Research and Development Orion Pharma  Espoo Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3402-023X","authenticated-orcid":false,"given":"Jens","family":"H\u00e4ggstr\u00f6m","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Medicine and Animal Science, Department of Clinical Sciences, Small Animals Swedish University of Agricultural Sciences  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6117-4571","authenticated-orcid":false,"given":"Meri","family":"Ramela","sequence":"additional","affiliation":[{"name":"Quantitative Bioanalytics &amp; Biomarkers Orion Pharma  Espoo Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1773-2369","authenticated-orcid":false,"given":"Mira","family":"Korpivaara","sequence":"additional","affiliation":[{"name":"Animal Health Research and Development Orion Pharma  Espoo Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199904000-00011"},{"key":"e_1_2_13_3_1","unstructured":"Angell L. andC.Seymour.2015.\u201cPremedication With Alpha\u20102 Agonists \u2013 Procedures for Monitoring Anaesthetic.\u201dVet Times.https:\/\/www.vettimes.co.uk\/app\/uploads\/wp\u2010post\u2010to\u2010pdf\u2010enhanced\u2010cache\/1\/premedication\u2010with\u2010alpha\u20102\u2010agonists\u2010procedures\u2010for\u2010monitoring\u2010anaesthetic.pdf."},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.229.10.1591"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08672"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2023.107266"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.40.2.150"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2011.04.001"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.applanim.2010.04.003"},{"key":"e_1_2_13_10_1","unstructured":"EMA.1998.\u201cClomicalm: EPAR \u2013 Summary for the Public.\u201dhttps:\/\/medicines.health.europa.eu\/veterinary\/en\/600000004048."},{"key":"e_1_2_13_11_1","unstructured":"EMA.2008a.\u201cFluoxevet 32 mg Tablets for Dogs.\u201dhttps:\/\/medicines.health.europa.eu\/veterinary\/en\/600000003478."},{"key":"e_1_2_13_12_1","unstructured":"EMA.2008b.\u201cReconcile: EPAR \u2013 Summary for the Public.\u201dhttps:\/\/medicines.health.europa.eu\/veterinary\/en\/600000003478."},{"key":"e_1_2_13_13_1","unstructured":"EMA.2021.\u201cTessie: EPAR \u2013 Summary for the Public.\u201dhttps:\/\/medicines.health.europa.eu\/veterinary\/en\/600000004664."},{"key":"e_1_2_13_14_1","unstructured":"EMA.2023.\u201cSPC Tessie 0.3 mg\/mL Oral Solution for Dogs.\u201dhttps:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/2023\/20230830160281\/anx_160281_en.pdf."},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013501994"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0319886"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.5326\/15473317\u201036\u20102\u2010107"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.235.6.705"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jveb.2022.11.003"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.104045"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.5326\/15473317\u201037\u20104\u2010313"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42826\u2010020\u201000078\u20106"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.70017"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0195\u20105616(91)50030\u20109"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jveb.2016.02.005"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jveb.2010.10.004"},{"key":"e_1_2_13_27_1","first-page":"256","volume-title":"Manual of Clinical Behavioral Medicine for Dogs and Cats","author":"Overall K. L.","year":"2013"},{"key":"e_1_2_13_28_1","volume-title":"Manual of Clinical Behavioral Medicine for Dogs and Cats","author":"Overall K. L.","year":"2014"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1207\/S15327604JAWS0302_2"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2008.04.012"},{"issue":"1","key":"e_1_2_13_31_1","first-page":"18","article-title":"Effects of Reconcile (Fluoxetine) Chewable Tablets Plus Behavior Management for Canine Separation Anxiety","volume":"8","author":"Simpson B. S.","year":"2007","journal-title":"Veterinary Therapeutics"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917\u2010025\u201005074\u20103"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.1995.56.03.275"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2016.11.003"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.70098","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvp.70098","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.70098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:21:48Z","timestamp":1786029708000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.70098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":33,"alternative-id":["10.1111\/jvp.70098"],"URL":"https:\/\/doi.org\/10.1111\/jvp.70098","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"2025-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jvp.70098"}}